That is a totally abstract metric which has zero significance in today's environment. We need more help at HQ, and in fact are recruiting interns at a record rate. Your SG&A metric is a joke !
Rova T Crash And Burn
- Thread starter anonymous
- Start date
-
- Tags
- None
That is a totally abstract metric which has zero significance in today's environment. We need more help at HQ, and in fact are recruiting interns at a record rate. Your SG&A metric is a joke !
The fact that our CEO and CFO repeatedly cite SG&A when discussing the numbers relative to peers means it should mean something to you. AbbVie may be right-sized for an old-time primary care company but is out of sync when measured against competitors like Amgen. If we want to be a biotech, then we should act like it. Look at HQ functions relative to Amgen's and they are overweight.
Being that's the case I stand corrected. Thank you.
Extremely negative clinical data that missed expectations was released by Abbvie on the DBL3001 study in which it was assessing the addition of ibrutinib to a chemotherapy regiment consisting of five different agents. These agents included rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). The treatment was compared to R-CHOP plus placebo. Currently, R-CHOP is the standard of care for patients with newly diagnosed DLBCL Stocks DOWN −$2.59 (2.62%)
Down −$3.87 (3.92%) closed at $94.96. Richard G. is crapping his pants.
Stock price will likely now not reflect Rova-T so if it can be resurrected, it will be gravy. That said, AbbVie's pipeline is not exactly robust which will continue to drag the stock price a bit. C-Suite probably thinking it has to reduce the size of the company to reflect Humira's anticipated decline (probably accelerated from what was projected because of Trump taking action on recent price industry increases which will limit ability to keep raising price) and possibly make an acquisition. Rick will not want stock to languish so I think will make some sort of move in 2018 (e.g., layoffs or deal or both).
AbbVie announced that a combination regimen of its blockbuster cancer drug, Imbruvica (ibrutinib), failed in a phase III study – DBL3001 – evaluating it as first-line treatment for diffuse large B-cell lymphoma (“DLBCL”). The drug failed to improve event-free survival (“EFS”) compared to current standard of care.
The previous post is right. Pipeline is weak and seemingly evaporating in late stage trials. Rick's deals are not panning out. So much for retirement. AbbVie will have to layoff people to adapt its size to a decline in humira as the pipeline is unable to fill the gap. The only other alternative is a deal/merger. Layoffs in either case.
The house of cards is tumbling down. Fire Rick NOW !!!!!!!
AbbVie Inc
NYSE: ABBV
$89.24 USD DOWN −$5.16 (5.47%)
Jul 19
AbbVie Inc
NYSE: ABBV
$89.24 USD DOWN −$5.16 (5.47%)
Jul 19
Heres what sparked todays big decline
Citron Research @CitronResearch 52m52 minutes ago
$ABBV the next great drug short. TGT price $60 Gottlieb's comments for biosimilars and the removal of safe harbor is a DIRECT hit on Abbvie's abuse of Humira. Citron to release a series of reports detailing the Dirty Money. POTUS, AMZN, and now FDA on the case $60 in 12 months
Abbv 87.84 USD −6.56 (6.95%)
Citron Research @CitronResearch 52m52 minutes ago$ABBV the next great drug short. TGT price $60 Gottlieb's comments for biosimilars and the removal of safe harbor is a DIRECT hit on Abbvie's abuse of Humira. Citron to release a series of reports detailing the Dirty Money. POTUS, AMZN, and now FDA on the case $60 in 12 months
Abbv 87.84 USD −6.56 (6.95%)
So POTUS, AMZN, and FDA are investigating Abbvie's abuse of Humira and Dirty Money . As you saw in my previous post on other threads, i explained there will be breaking news that will send abbv back to $60 where it will STAY !
The Legendary short-side reporters at Citron are pointing to the fact that it believes that ABBV is abusing the medical community through hefty pricing on its drug known as Humira. Humira is incredibly important to the revenue seen at AbbVie, and the removal of safe harbor will force declines in pricing. Therefore, ABBV will likely see great reductions in revenue.
Fire Rick NOW !!!!
Fire Rick NOW !!!!
If people don't realize Trump is going to go after Humira price increases, our patent strategy, and look at whether AbbVie's commercial practices inhibit competition, see these comments issued today by FDA, "While less than 2 percent of Americans use biologics, they represent 40 percent of total spending on prescription drugs. So, enabling a path to competition for biologics from biosimilars is a key to reducing costs..." Trump is also calling individual CEOs (Pfizer) to bully them into backing off price increases.
Wake up. Humira's glory days are waning. The stock is heading to $60 according to Citron. Layoffs coming. I don't see any way around that fact given the weak pipeline. Too bad Rick wasted so much money on corporate jets. For all of those who post that they want Rick fired, who would you make the next CEO?
Wake up. Humira's glory days are waning. The stock is heading to $60 according to Citron. Layoffs coming. I don't see any way around that fact given the weak pipeline. Too bad Rick wasted so much money on corporate jets. For all of those who post that they want Rick fired, who would you make the next CEO?
Because of stock performance this year, Ricks total 2018 salary including options and incentives, will be slashed by 45%. That record $21M from 21017 will be around $11M for this year.
Still not too shabby for a College Drop Out.
In six months the only people working here will be the ones who can't find jobs anywhere else. It is a sinking ship.